Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
51
resultados
Última actualización
28/08/2026 [06:46:00]
Resumen de: AU2025259635A1
The present disclosure provides systems and methods for generating a lipid nanoparticle. The system may comprise a conduit comprising a first inlet configured to introduce a nucleic acid. The conduit may further comprise a second inlet configured to introduce one or more lipid components of the lipid nanoparticle. The conduit may further comprise an outlet, wherein the nucleic acid and the one or more lipid components are joined in the outlet. The system may further comprise a static mixer. The nucleic acid and the one or more lipid components may be mixed in the static mixer to generate a mixture fluid. A polydispersity index of the mixture fluid may be no greater than about 0.25.
Resumen de: AU2025228064A1
The present disclosure relates generally to pharmaceutical compositions (e.g., solid oral dosage forms) of the compound of Formula I: Also disclosed are methods of treating or preventing human immunodeficiency virus (HIV) infection in a human, including orally administering to the human the solid oral dosage forms or pharmaceutical compositions disclosed herein.
Resumen de: AU2025221590A1
Lipid-based nanoparticles containing lipids, phenolic compounds, and, optionally, metal ions are provided. In certain forms, the nanoparticles adopt non-lamellar, lyotropic, liquid crystalline structures. Bioactive lipid-based nanoparticles containing one or more active agents are also provided as are methods of treating diseases or conditions with said bioactive lipid-based nanoparticles and formulations thereof.
Resumen de: AU2026216794A1
PROTEIN-LOADED PLGA NANOSPHERES The present disclosure provides compositions comprising protein encapsulated nanoparticles, and methods of making said compositions. In an aspect, a composition may comprise a drug delivery vector and a therapeutic substance, wherein the composition elutes at least 1.0 pg of the therapeutic substance per 100,000 particles of the drug delivery vector over a period of time under conditions of a drug delivery vector release buffer, wherein the therapeutic substance, drug delivery vector and drug delivery vector release buffer comprise a solution, wherein the solution is centrifuged and a portion stored at about 1 to 10º C, and wherein the elution of the therapeutic substance is determined by ELISA assay. This disclosure further describes a method of controlling an immunophenotype in a patient suffering from a disease which impacts the immune system. PROTEIN-LOADED PLGA NANOSPHERES ug - u g
Resumen de: AU2026213981A1
Abstract Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed. Abstract
Resumen de: AU2026213995A1
Abstract The present invention relates to the mRNA vaccine of coronavirus spike protein with deletion of glycosites in the receptor binding domain (RBD), the subunit 1 (S1) domain, or the subunit 2 (S2) domain, or a combination thereof. The vaccine elicits broadly protective immune responses coronavirus and variants thereof. Abstract
Resumen de: AU2025220004A1
There is provided a hybrid nanofibrous mat comprising electrospun nanofibers formed by electrospinning of a polymer mix and porous silica capsules dispersed throughout the electrospun nanofibers during the electrospinning, the porous silica capsules having a hydrophobic liquid core containing an active. There is also provided a method of producing a hybrid nanofibrous mat comprising providing porous silica capsules having a hydrophobic liquid core containing an active, forming an electrospinning solution comprising the porous silica capsules and an electrospinning polymer mix, homogenising the electrospinning solution to fully disperse the porous silica capsules, and electrospinning the electrospinning solution to form the hybrid nanofibrous mat.
Resumen de: WO2025090525A1
The disclosure provides conjugates comprising a targeting moiety a lipid nanoparticle (LNP) encapsulating a therapeutic agent (e.g., payload) for delivery to immune cells. The conjugates can be delivered to immune cells ex vivo or formulated in a pharmaceutical composition and can be directly administered to a subject in need of (i.e., via in vivo administration).
Resumen de: EP4796551A1
0001 The purpose of the invention described herein is to provide a compound having a novel chemical structure that is usable for lipid nanoparticles. Disclosed are a compound represented by formula (I) (in the formula, R<1> and R<2> are each independently a C10-24 chain hydrocarbon group, R<3> is a C1-22 chain hydrocarbon group) and lipid nanoparticles containing the compound.
Resumen de: EP4796213A1
0001 While conventional hydrogel manufacturing methods employing physical or chemical stimuli require sophisticated processes and can compromise the activity and structural integrity of particles-particularly when biological materials sensitive to external reactions are involved-the hydrogel and the preparation method thereof using an Aqueous Two-Phase System (ATPS) provided by the present invention enable the simultaneous formation of the hydrogel and encapsulation of desired nanoparticles within the hydrogel. The present invention successfully achieves the concentration of desired nanoparticles within a hydrogel with high yields through a simplified process. Furthermore, by facilitating concurrent concentration and hydrogel formation, the present invention relates to a hydrogel and a preparation method thereof using an ATPS that significantly reduces manufacturing time and costs.
Resumen de: EP4796555A1
The present invention relates to a novel lipid compound for tissue-specific delivery and a lipid nanoparticle (LNP) composition comprising the same. The lipid nanoparticle comprises, as a component, a lipid compound modified such that an active substance therein is selectively delivered into cells of a specific tissue such as lymph nodes, spleen, retina, tumors, brain, liver, and the like in vivo, thereby preventing side effects and safely achieving desired therapeutic efficacy. These tissue-specific, non-viral LNP delivery systems can be effectively utilized for the prevention of infectious diseases and the treatment of rare and intractable (inherited) diseases (e.g., macular degeneration, diabetic retinopathy, inherited retinal diseases, cancer, brain diseases, liver diseases, etc.), where efficient and selective delivery to the targeted site in the body is crucial.
Resumen de: EP4796109A2
The present invention provides methods and compositions for treating a hyperplasia (such as cancer, restenosis, or pulmonary hypertension) by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and an albumin based upon the status of an mTOR-activating aberration.
Resumen de: WO2025083423A1
The invention relates to a self-assembling conjugate molecule, the conjugate molecule comprising a hydrophobic polymer covalently bound to human serum albumin (HSA) only at residue Cys34; or a hydrophobic polymer covalently bound to a non-human serum albumin protein only at an equivalent residue to Cys34 of HSA; and associated compositions, uses and methods of treatment.
Resumen de: WO2025083617A1
The present disclosure includes a composition including a) one or more nucleic acid constructs, wherein the one or more nucleic acid constructs encode: at least one of Replicase 68 (Rep68) and Replicase 78 (Rep78); and at least one protein of viral origin having nucleic acid replication and/or transgene amplification promotion activity, and b) nucleic acid construct comprising a coding region encoding at least one gene of interest (GOI) and at least one inverted terminal repeat (ITR) sequence on each side of the GOI, and methods of making and using the composition.
Resumen de: WO2025082973A1
The present invention relates to ionizable lipids for use in lipid nanoparticles, lipid nanoparticle formulations comprising these ionizable lipids, alone or in combination with other lipids and/or polymers. The lipid nanoparticles formulations may be formulated with nucleic acids for their delivery to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration.
Resumen de: EP4796527A1
0001 The present invention relates to a cationic lipid and a method for preparing same, and more specifically to: a cationic lipid which, due to the specific structure thereof, forms (or is capable of forming) a complex with an anionic drug, and thus is useful for drug delivery; and a method for preparing same.
Resumen de: WO2025085881A1
Nanoemulsions (NEs) and nanocapsules (NCs), are disclosed that include nanoparticles that can readily diffuse/distribute throughout the nervous system and that can deliver a therapeutic agent thereto. Methods of making and using the same also are disclosed, especially for treating diseases and/or disorders in which delivery of a therapeutic agent to and/or throughout the nervous system are needed.
Resumen de: WO2025024824A1
The present disclosure relates to compositions and methods for targeting vesicles to specific tissue and cell types. Also disclosed are compositions and methods for delivering therapeutic molecules, including nucleic acids and nucleic acid derivatives, to specific cells or tissues using vesicles with cell and tissue-specific targeting moieties expressed on their surfaces.
Resumen de: CN122624419A
本发明涉及药物制剂及制备与应用技术领域，特别涉及一种具有铜死亡与化学动力学协同作用的仿生无载体纳米粒、制备方法及应用。该纳米粒以没食子酸与铜离子通过配位自组装形成金属酚网络为核心，并包覆中性粒细胞膜构建而成。其中，铜离子可通过类芬顿反应催化过氧化氢生成羟基自由基，并诱导病变滑膜细胞发生铜死亡，从而高效清除炎症细胞；没食子酸发挥抗炎与抗氧化作用，协同调节炎症微环境；中性粒细胞膜赋予纳米粒主动靶向至炎症关节的能力，有效减轻了脱靶毒性。本发明提供的纳米粒具有靶向性强、生物相容性高、制备简便、协同治疗机制明确等优点，可显著提升类风湿关节炎的治疗效果并降低系统性毒副作用。
Resumen de: CN122629047A
本发明公开了一种抑制班达病毒复制的siRNA、RNA递送系统及其应用，涉及核酸药物与抗病毒治疗技术领域。针对SFTSV的S节段保守区域设计了siRNA，其不仅能靶向SFTSV的不同毒株的S节段，还能靶向其他的班达病毒的S节段，在细胞模型中可降低病毒RNA水平、病毒蛋白表达及病毒滴度，从而抑制班达病毒复制。此外，本发明还提供了RNA递送系统，可以实现siRNA的体内有效递送并增强抗病毒效果。因此，本发明提供的siRNA有望用于SFTSV等多种班达病毒感染的预防或治疗。
Resumen de: CN122624461A
本发明属于药物与疾病治疗技术领域，具体涉及7‑表紫杉醇在制备治疗非酒精性脂肪肝的药物中的用途。本发明通过体内、体外多模型验证，首次揭示7‑表紫杉醇（7‑epi‑paclitaxel）对非酒精性脂肪性肝病具有剂量依赖且可逆的“三阶”干预作用，并兼具“调脂‑抗炎‑抗纤维化”一体化优势，本发明的研究结果表明，7‑表紫杉醇可以用于制备治疗非酒精性脂肪肝的药物，同时保持极高安全性与依从性。
Resumen de: CN122624319A
本发明提供一种亲水型氧化铈纳米颗粒及其分散液。亲水型氧化铈纳米颗粒包括氧化铈纳米颗粒内核以及包覆于其表面的亲水高分子化合物，氧化铈纳米颗粒中铈元素以Ce3+和Ce4+两种价态共存。亲水高分子化合物包覆于氧化铈纳米颗粒表面，可提高其在水相体系中的分散性和稳定性。本发明还提供亲水型氧化铈纳米颗粒的制备方法，可在水相体系、常温常压条件下进行，工艺温和，操作简便，所得亲水型氧化铈纳米颗粒具有良好的自由基清除能力、分散稳定性和氧化应激调控活性，可在水体系中形成稳定分散液，并在细胞和动物氧化应激模型中表现出较好的抗氧化及组织保护作用。本发明还提供亲水型氧化铈纳米颗粒或其分散液在抗氧化、氧化应激调控及相关制剂中的应用。
Resumen de: CN122624620A
本发明公开一种高效穿透血脑屏障的负载多肽的黄精外泌体的制备方法，包括以下步骤：（1）从新鲜黄精中提取黄精外泌体，得到纯化后的黄精外泌体；（2）将多肽与纯化的黄精外泌体共孵育，得到所述高效穿透血脑屏障的负载多肽的黄精外泌体。本发明制备得到的黄精外泌体，囊泡结构完整，将其负载多肽，包封率高，达91.23%。本发明制备得到的负载多肽的黄精外泌体具有更强抗氧化能力，并更易穿透血脑屏障。一方面，黄精外泌体高效递送多肽，使多肽更好发挥改善学习记忆力的作用，另一方面，黄精外泌体和多肽协同作用，共同增强了改善学习记忆力的效果。本发明为功能因子递送系统在中枢神经系统疾病中的应用提供了新思路，具有广阔的应用前景。
Resumen de: WO2025117815A1
Provided are lipid nanoparticles compositions comprising a payload, a helper lipid, a sterol, a PEG-lipid, an ionizable lipid, a permanently cationic lipids. Also provided herein are a method of delivering a payload to a cell in a lung of a subject by intravenous administration and a method for treating and/or preventing a lung disease in a subject in need thereof by intravenous administration. Also provided are a method for quantifying an amount of capped messenger RNA (mRNA) in an mRNA sample comprising contacting the mRNA with two or more of a nuclease, an alkaline phosphatase, and a polynucleotide kinase and separating the capped mRNA and the uncapped mRNA occurs using chromatography.
Nº publicación: CN122641477A 25/08/2026
Solicitante:
基因有限公司
Resumen de: WO2025106594A1
The present invention provides a pharmaceutical composition comprising an exosome encapsulating one or more cargo RNAs comprising a package RNA and one or more fusion proteins wherein the nucleotide sequence of the package RNA is at least about 80%, about 85%, about 90%, about 95% or about 100% identical to the nucleotide sequence of an elastin (ELN) gene or an elastin messenger RNA (mRNA) that also includes any isoforms. The present invention also provides a method of treatment of elastin deficient related illness in a subject using the pharmaceutical composition of the present inventin.
BOPI
Sede Electrónica
